324 related articles for article (PubMed ID: 19200447)
1. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.
Jones B; Zhan X; Mishin V; Slobod KS; Surman S; Russell CJ; Portner A; Hurwitz JL
Vaccine; 2009 Mar; 27(12):1848-57. PubMed ID: 19200447
[TBL] [Abstract][Full Text] [Related]
2. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.
Zhan X; Slobod KS; Krishnamurthy S; Luque LE; Takimoto T; Jones B; Surman S; Russell CJ; Portner A; Hurwitz JL
Vaccine; 2008 Jun; 26(27-28):3480-8. PubMed ID: 18499307
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B.
Zhan X; Hurwitz JL; Krishnamurthy S; Takimoto T; Boyd K; Scroggs RA; Surman S; Portner A; Slobod KS
Vaccine; 2007 Dec; 25(52):8782-93. PubMed ID: 18037543
[TBL] [Abstract][Full Text] [Related]
4. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
5. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections.
Hurwitz JL
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S126-8. PubMed ID: 18820573
[TBL] [Abstract][Full Text] [Related]
6. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
Mason JN; Elbahesh H; Russell CJ
J Virol; 2013 May; 87(10):5959-69. PubMed ID: 23514887
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.
Scaggs Huang F; Bernstein DI; Slobod KS; Portner A; Takimoto T; Russell CJ; Meagher M; Jones BG; Sealy RE; Coleclough C; Branum K; Dickey M; Buschle K; McNeal M; Makowski M; Nakamura A; Hurwitz JL
Hum Vaccin Immunother; 2021 Feb; 17(2):554-559. PubMed ID: 32750273
[TBL] [Abstract][Full Text] [Related]
8. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
9. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
[TBL] [Abstract][Full Text] [Related]
10. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
Durbin AP; Karron RA
Clin Infect Dis; 2003 Dec; 37(12):1668-77. PubMed ID: 14689350
[TBL] [Abstract][Full Text] [Related]
11. Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats.
Zhan X; Slobod KS; Jones BG; Sealy RE; Takimoto T; Boyd K; Surman S; Russell CJ; Portner A; Hurwitz JL
Int Immunol; 2015 May; 27(5):229-36. PubMed ID: 25477211
[TBL] [Abstract][Full Text] [Related]
12. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
[TBL] [Abstract][Full Text] [Related]
14. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
[TBL] [Abstract][Full Text] [Related]
15. Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses.
Russell CJ; Hurwitz JL
Viruses; 2021 May; 13(6):. PubMed ID: 34072332
[TBL] [Abstract][Full Text] [Related]
16. Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.
Russell CJ; Hurwitz JL
Expert Rev Vaccines; 2016; 15(2):189-200. PubMed ID: 26648515
[TBL] [Abstract][Full Text] [Related]
17. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.
Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.
Pennathur S; Haller AA; MacPhail M; Rizzi T; Kaderi S; Fernandes F; Bicha L; Schickli JH; Tang RS; Chen W; Nguyen N; Mathie S; Mehta H; Coelingh KL
J Gen Virol; 2003 Dec; 84(Pt 12):3253-3261. PubMed ID: 14645907
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector.
Wiegand M; Gori-Savellini G; Martorelli B; Bossow S; Neubert WJ; Cusi MG
Vaccine; 2013 Aug; 31(37):3888-93. PubMed ID: 23831325
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.
Alymova IV; Taylor G; Takimoto T; Lin TH; Chand P; Babu YS; Li C; Xiong X; Portner A
Antimicrob Agents Chemother; 2004 May; 48(5):1495-502. PubMed ID: 15105096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
